国家: 爱尔兰
语言: 英文
来源: HPRA (Health Products Regulatory Authority)
Escherichia coli, strain 08:K35, fimbrial adhesin F5, Inactivated; Bovine rotavirus, strain TM-91, Inactivated; Bovine coronavirus strain c-197 (inactivated)
Boehringer Ingelheim Vetmedica GmbH
QI02AL01
Escherichia coli, strain 08:K35, fimbrial adhesin F5, Inactivated; Bovine rotavirus, strain TM-91, Inactivated; Bovine coronavirus strain c-197 (inactivated)
Suspension for injection
POM: Prescription Only Medicine as defined in relevant national legislation
bovine rotavirus + bovine coronavirus + escherichia
2022-08-19
1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fencovis suspension for injection (AT, BE, CZ, DE, EL, ES, FR, IE, IT, LU, NL, PT, UK(NI)) Fencovis RCE vet suspension for injection (FI, NO, SE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 ml dose contains: ACTIVE SUBSTANCE: Inactivated _E. coli_ expressing F5 (K99) adhesin, strain O8:K35 RP ≥ 1* Inactivated bovine rotavirus, serotype G6P1, strain TM-91 RP ≥ 1* Inactivated bovine coronavirus, strain C-197 RP ≥ 1* * Relative potency (RP): level of antibodies in sera of vaccinated guinea pigs as determined by ELISA in comparison with the reference serum obtained after vaccination of guinea pigs with a vaccine batch that has successfully passed the challenge test in the target animals. ADJUVANTS: Aluminium hydroxide 6 mg Quillaja saponin (Quil A) ≤ 0.4 mg EXCIPIENTS: Thiomersal 0.2 mg Formaldehyde ≤ 1 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Appearance: orange, pink to deep pink liquid with whitish sediment, which is homogenously dispersed after shaking. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (pregnant heifers and cows). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and _E. coli_ expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and _E. coli_ expressing F5 (K99) adhesin. In calves fed with colostrum and milk from vaccinated cows for the first week of life, laboratory studies conducted with heterologous challenge strains (a G6 BRV strain, a BCV strain and a K99 _E. coli_ strain) have demonstrated that these antibodies: - prevent neonatal diarrhoea caused by bovine rotavirus and _E. coli_ expressing F5 (K99) adhesin, - reduce the incidence and severity of neonatal diarrhoea caused by bovine coronavirus, - reduce faecal shed阅读完整的文件